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Abstract 
Choriocarcinoma is a gestational trophoblastic disease that carries high mortality. As this 
disease is highly responsive to chemotherapy, early diagnosis could lead to a favorable 
outcome. We report a case of metastatic pulmonary choriocarcinoma presented with 
hemoptysis and respiratory failure in a young woman at her third trimester. This report 
discusses the dilemma in deriving the diagnosis of choriocarcinoma and briefly outlines 
the current approaches to its treatment. Potentially life-threatening choriocarcinoma 
should be considered in all unusual chest radiographs of women of childbearing age. 
Clinicians should be aware of this possibility and proceed with the most appropriate 
diagnostic procedures. 
 
Introduction 
We report a case of metastatic pulmonary choriocarcinoma that presented with 
hemoptysis and respiratory failure. The diagnosis and management of this case are 
discussed. 
Case Report 
Our patient is a 29-year-old G5P3+2 at her 34th week of gestation. Her past obstetric history reveals 
that she has had 2 full-term spontaneous deliveries and 2 terminations. 
She was first seen at 19 weeks of gestation and was subsequently admitted at 34 weeks for high blood 
pressure of 143/79 mm Hg and albuminuria (++). Although the blood pressure remained elevated, there 
were no signs of clinically significant preeclampsia. The fetus growth corresponded to the course of 
pregnancy.  
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The patient was dyspneic and complained of having a cough and sputum with bloody streaks 3 days 
after admission. Oxygen saturation was 90% in room air, but increased to 95% upon the administration 
of 2 l/min of oxygen via a nasal cannula. Systolic ejection murmur was detected at the left sternal 
border. Contrast echocardiographic examination of the heart showed a secundum atrial septal defect 
(ASD) of 1.8 cm with left to right shunt and pulmonary hypertension (fig. 1). Medical history revealed 
that the patient had had recurrent hemoptysis for a week prior to admission. Chest X-ray showed 
diffuse haziness over both lung fields. 
Induction of labor was subsequently performed because cardiotocographic monitoring revealed a 
suboptimal fetal condition. A live birth of 2.14 kg, with an Apgar score of 8 at 1 and 5 min, was 
delivered by vaginal delivery. 
The patient was then admitted to the Intensive Care Unit because preeclampsia and suboptimal 
oxygenation were apparent. She was put on magnesium sulfate and diltiazem infusion for preeclampsia. 
Infective and rheumatological causes for the bilateral pulmonary infiltrates were sought. Signs of 
preeclampsia were resolved 2 days after treatment, but the patient remained dyspneic with increasing 
pulmonary infiltrates (fig. 2a). Although computed tomography (CT) of the thorax ruled out 
pulmonary embolism, extensive patchy consolidation and nodular infiltrates were found (fig. 2b). 
Two days later, the patient was intubated and ventilated for progressive hypoxemia. She remained 
difficult to oxygenate, requiring a high level of positive end-expiratory positive pressure, inspired 
oxygen, and nitric oxide. Microbiological and rheumatological investigations revealed no further 
significant findings relating to the pulmonary infiltrates. Trophoblastic disease was suspected and the 
first measured serum gestational human chorionic gonadotropin (hCG) level was 614,068 IU/l. 
Metastatic choriocarcinoma was subsequently confirmed by an open lung biopsy, and methotrexate 
(MTX) was given immediately after the operation. 
The patient’s hCG levels dropped significantly after an initial dose of MTX, but they increased again 
on day 10. She was then given a combined course of etoposide (VP 16), MTX, and bleomycin. The hCG 
levels decreased substantially, and further 6 cycles were given. Her condition improved gradually, and 
she was transferred to the gynecological oncology centre, where she was subsequently discharged. 
During regular follow-ups, she was found to have raised hCG levels 2 months after her last dose of 
chemotherapy. Whole-body CT scan and lumbar puncture revealed lung and suspected brain 
metastases. She was then put on chemotherapy using etoposide-methotrexate-actinomycin D-
cyclophosphamide-vincristine (EMA-CO). Her hCG levels returned to normal after 4 more cycles of 
EMA-CO, and she remained in remission. 
Discussion 
Gestational Trophoblastic Neoplasia (GTN) 
GTN was previously regarded as a gynecologic malignancy with high mortality, but it 
has recently become one of the most curable malignancies as it is chemosensitive in 
nature [1]. The incidence of gestational trophoblastic disease (GTD) varies between 1 in 
120 pregnancies in some parts of Asia and South America and 1 in 1,200 in the United 
States
 [2]. Although choriocarcinoma, a form of GTD, is relatively rare, cases have been 
found in Africa, Asia and South America, with a majority of them occurring in women 
aged below 35 [3]. 
The Origin of Choriocarcinoma and Its Associated Symptoms 
Choriocarcinoma has a tendency towards early vascular invasion with widespread 
dissemination. Trophoblastic tumors are frequently hemorrhagic, since they are often 
perfused by a network of fragile vessels. Symptoms of metastases may therefore result 
from spontaneous bleeding at metastatic foci.  
Case Rep Oncol 2009;2:133–139 
DOI: 10.1159/000228893 
Published online: July 29, 2009  © 2009 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
 
 
135
Recurrent hemoptysis seems to be the most frequent symptom in pulmonary 
choriocarcinoma, which is often associated with chest pain and persistent cough [4], with 
distal metastases commonly present in the brain, vagina, and kidneys. There are 3 main 
types of pulmonary choriocarcinoma that are caused by hematogenous metastases [5, 6]. 
First, well-defined and rounded nodular lesions are observed in 65–95% of patients and 
some nodules may cavitate. Second, 5–15% of cases have military or alveolar pattern with 
indefinite borders simulating an inflammatory process on chest X-ray. Third, it may 
present with pulmonary infarction and hypertension due to tumor embolisation of the 
pulmonary artery. 
Approaches to Making the Correct Diagnosis 
The initial diagnosis was difficult because the patient had numerous respiratory 
problems. The preliminary diagnosis was thought to be primary pulmonary disease 
because of the apparent hemoptysis, dyspnea, and a diffuse pulmonary infiltration. The 
patient’s rapidly deteriorating condition could not be explained as there were no 
autoimmune makers or signs of infection, and her CT of the thorax already ruled out 
pulmonary embolism. The incidental finding of the ASD with pulmonary hypertension 
was thought to be the culprit, but she did not respond to heart failure treatments. The 
elevated hCG levels coupled with other clinical presentations suggested metastatic 
choriocarcinoma, which was subsequently confirmed by the open lung biopsy. 
Peripartum hemoptysis carries a broad differential diagnosis that encompasses a 
variety of causes including (i) thromboembolic diseases, such as pulmonary embolism; 
(ii) vascular pathology, such as vasculitis/arteriovenous malformation; (iii) inflammation; 
(iv) infection; (v) autoimmune disease, such as microscopic polyangiitis or pulmonary 
renal syndrome; (vi) peripartum cardiomyopathy, and (vii) primary or secondary 
malignancy. 
Metastatic workup in this group of patients should include a variety of imaging 
techniques as well as serum hCG measurements. Most hepatic metastases in patients with 
abnormal liver function tests are typically shown in liver ultrasonography and CT 
imaging. CT and magnetic resonance imaging brain scans can facilitate the early 
diagnosis of asymptomatic cerebral lesion. In the absence of lung or vaginal metastasis, 
the risk of cerebral and hepatic spread is exceedingly low [7]. 2
18F-fluoro-2-deoxy-D-
glucose positron emission tomography (FDG-PET) can assist differential diagnosis by 
locating the possible metastatic or persistent lesions and by providing information on 
tumor activity [8]. 
The Significance of hCG 
hCG, a tumor product of biological and clinical significance, is a glycoprotein that 
consists of an alpha subunit, which is structurally similar to luteinizing hormone (LH) 
and thyroid stimulating hormone, and a beta subunit, which provides the antigenic 
uniqueness that permits its detection using radioimmunoassay [9]. After pregnancy 
termination, there is a predictable decrease in β-hCG titer levels. By the 8th postpartum 
week, these values are within the normal physiological range of LH secretion. Persistent 
elevation of hCG levels in postpartum patients should prompt an immediate intensive 
diagnostic study.  
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Although hCG is a sensitive and specific tumor maker for monitoring response to 
treatment, false-positives sometimes occur at low levels due to the presence of non-
specific heterophilic antibodies in the patient’s sera. An additional urine pregnancy test 
may be useful as the heterophilic antibodies are not excreted in the urine. The lack of 
dilution parallelism and the absence of urine reactivity indicate that the molecule 
measured was a pseudogonadotropin (i.e. phantom hCG), which is the interfering 
substance in the hCG test [10]. Care is needed in interpreting persistently low levels of 
hCG in patients without a history of trophoblastic disease in order to avoid unnecessary 
intervention. 
Treatment of GTN 
High-risk metastatic disease is initially treated with combination chemotherapy with 
or without adjuvant radiotherapy or surgery. While several drug combinations have been 
used, the EMA-CO is the most effective with the reported 5-year survival rate at around 
85% [11, 12]. The use of a new anti-cancer agent paclitaxel [13] or high doses of 
chemotherapy coupled with autologous bone marrow support and G-CSF have been 
reported [14]. Cisplatin, vinblastine, and bleomycin may also be effective as a 2nd-line 
therapy [15, 16]. 
There is no consensus, however, on the duration of chemotherapy. It is recommended 
that the chemotherapy should be stopped when the hCG levels become undetectable, yet 
some recommend additional courses for high-risk GTN. The ultimate decision should be 
based on whether the patient falls into a low- or a high-risk category and the gradient of 
the hCG regression curve. 
Adjuvant surgical procedures, especially hysterectomy and pulmonary resection, for 
chemotherapy-resistant disease as well as procedures to control hemorrhage are 
important approaches to the management of high-risk GTN [17]. Radiotherapy with 
concurrent chemotherapy has been used for CNS metastasis with 5-year survival 
averaging at 50% [18]. 
Conclusions 
The possibility of choriocarcinoma manifestation, albeit small, should be considered in 
all unusual chest radiographs of women of childbearing age. Early diagnosis is crucial, as 
this condition is very treatable. Clinicians should be aware of this possibility and proceed 
with the most appropriate diagnostic procedures. 
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Fig. 1. Transthoracic echocardiogram (subcostal view) showing secundum atrial septal defects with left 
to right shunt. 
 
 
Fig. 2. Chest X-ray (a) and computer tomography of the thorax (b) show patchy and extensive nodular 
infiltrates. 
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